Semin intervent Radiol 2021; 38(04): 453-459
DOI: 10.1055/s-0041-1735617
Review Article

Recognizing and Managing Adverse Events in Y-90 Radioembolization

Grace L. Laidlaw
1   Section of Interventional Radiology, Department of Radiology, University of Washington, Seattle, Washington
,
Guy E. Johnson
1   Section of Interventional Radiology, Department of Radiology, University of Washington, Seattle, Washington
› Author Affiliations
Zoom Image

Abstract

Transarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.



Publication History

Article published online:
07 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA